Pre-market
Loading markets…

Advertisement

Stocks

What's Going On With Fennec Pharmaceuticals Inc Stock Thursday?

By Wealth Awesome -

Follow live quotes and coverage.

Stocks & ETFs:FRX.TO

Follow FRX

Photos provided by Pexels

Fennec Pharmaceuticals Inc stock sees notable price movement amidst recent company announcements.

Fennec Pharmaceuticals Inc (FRX.TO) has experienced a positive price action this week, closing at C$14.88 after a 7.44% increase in one day and a 6.67% rise over the week. This upward trend may be attributed to recent announcements regarding share offerings and financial performance.

Advertisement

Fennec Pharmaceuticals Inc

FRX.TO

Full stock page →

FRX.TO

Fennec Pharmaceuticals Inc

Source:WealthAwesomeWealthAwesome
↑ $5.93 (66.41%)
120 day period
$8.10$12.86$17.63Apr 6Jul 7Oct 9

Market cap

$521.10M

52W high

$17.64

52W low

$7.59

1W change

+2.41%

Beta

1.23

Analyst Price Targets

Based on analyst covering FRX · as of Sep 17, 2026

📈

Wall Street analysts forecast FRX stock price to rise 529.7% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$93.57

+529.7% Upside

Current Price

C$14.86

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on FRX's historical volatility

HistoricalForecast68%95%
C$6.77C$11.36C$15.96C$20.56C$25.15C$29.75TodayMay 21Jul 29Oct 9Nov 21Jan 4Feb 16

30-Day Vol

59.4%

Annualized

90-Day Vol

58.2%

Annualized

Trend (90d)

-12.8%

Annualized drift

90d Mean

C$14.20

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$14.64C$11.92 – C$17.97
60 trading daysC$14.41C$10.79 – C$19.26
90 trading daysC$14.20C$9.95 – C$20.25

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Investor takeaway: Fennec Pharmaceuticals has shown resilience in its stock performance, supported by recent financial results and share offerings. Investors should monitor the company's ongoing developments closely.

Fennec Pharmaceuticals reports a year-to-date stock increase of 42.94%.

The stock has demonstrated significant volatility, with a 52-week range of C$7.59 to C$15.48, indicating potential for both risk and reward.

Bull case

The company’s recent announcements point to strong growth, highlighted by record product sales and strategic financing efforts. These moves could enhance its position in the market.

Bear case

Despite the recent price gains, Fennec Pharmaceuticals is still operating at a loss, raising concerns about its long-term profitability and cash flow sustainability.

Recent Price Action

Advertisement

Fennec Pharmaceuticals Inc has reported a significant increase in its stock price this week, with a closing price of C$14.88. The stock has gained 7.44% in just one day and 6.67% over the week, reflecting a strong performance in the midst of ongoing developments.

Company News and Catalysts

While there are no major company news announcements this week, recent headlines indicate that Fennec Pharmaceuticals has been active in the capital markets. Notably, the company priced an underwritten public offering of common shares aiming to raise approximately $35 million. Additionally, they closed a private offering in Canada, further supporting their financial position. These actions suggest a proactive approach to funding and growth.

Technical Picture

The technical indicators for Fennec Pharmaceuticals show a 50-day moving average of C$13.93, which is 6.8% above the current price, and a 200-day moving average of C$11.41, indicating a 30.5% premium. The stock is currently trading in the upper range of its 52-week performance, which spans from C$7.59 to C$15.48. The stock's beta is 1.07, suggesting slightly higher volatility compared to the broader market. Volume has been low, with the latest trading volume at 101 shares, representing only 0.21 times the 20-day average volume of 474 shares.


Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: August 6, 2026
Last Updated: August 6, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26

Sponsored links

Advertisement